These polymorphisms were chosen because of either their known impacts on different cell processes (e.g., PI3K/AKT pathway, DNA damage repair, immune response regulation) or of evidence of a relationship with TZ/PZ treatment in BC patients. This evidence concerns the gene PIK3CA and breast cancer.